- Trials with a EudraCT protocol (1,653)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (5)
1,653 result(s) found for: Kidney disease.
Displaying page 1 of 83.
EudraCT Number: 2021-002551-11 | Sponsor Protocol Number: HP-CKDPKD | Start Date*: 2022-01-18 | ||||||||||||||||
Sponsor Name:Aarhus University | ||||||||||||||||||
Full Title: Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI | ||||||||||||||||||
Medical condition: Chronic kidney disease and polycystic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001924-37 | Sponsor Protocol Number: HJU1 | Start Date*: 2013-11-05 | |||||||||||
Sponsor Name:Fredericia Hospital | |||||||||||||
Full Title: Relaxation of the ureter during ureterorenoscopy | |||||||||||||
Medical condition: Elevated pressure in the upper urinary tract during ureterorenoscopy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004115-39 | Sponsor Protocol Number: PoCKET | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology | |||||||||||||
Full Title: Subacute Effect of Tolvaptan on Total Kidney Volumen in Adult Patients with Autosomal Dominant Polycystic Kidney Disease | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney DIsease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001485-16 | Sponsor Protocol Number: CRAD001ADE12 | Start Date*: 2006-12-15 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal domin... | |||||||||||||
Medical condition: polycystic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017849-57 | Sponsor Protocol Number: PCLD004 | Start Date*: 2011-03-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||||||||||||||||||||||
Full Title: Somatostatin analogues as a volume reducing treatment of polycystic livers | |||||||||||||||||||||||||||||||||
Medical condition: Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001519-10 | Sponsor Protocol Number: ALN-GO1-008 | Start Date*: 2022-04-25 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Di... | |||||||||||||
Medical condition: Recurrent calcium oxalate kidney stone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004099-26 | Sponsor Protocol Number: 6.version,september2011 | Start Date*: 2009-12-10 | ||||||||||||||||
Sponsor Name:Departmnet of nephrology | ||||||||||||||||||
Full Title: Randomised trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function. | ||||||||||||||||||
Medical condition: decreased renal function (CKD II-IV), creatinin clearance 15-90 ml/min | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005017-37 | Sponsor Protocol Number: TheDIPAK1study | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:DIPAK Consortium | |||||||||||||
Full Title: A randomised, controlled clinical trial assessing the efficacy of Lanreotide to halt disease progression in ADPKD | |||||||||||||
Medical condition: First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second,... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022994-32 | Sponsor Protocol Number: 34009 | Start Date*: 2011-06-24 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease | ||||||||||||||||||
Medical condition: Chronic kidney disease End stage renal disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005991-36 | Sponsor Protocol Number: 156-12-204 | Start Date*: 2022-10-07 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidne... | |||||||||||||
Medical condition: Autosomal Recessive Polycystic Kidney Disease (ARPKD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004223-12 | Sponsor Protocol Number: CT-1KIDN-01 | Start Date*: 2012-08-27 | |||||||||||
Sponsor Name:Digna Biotech S.L. | |||||||||||||
Full Title: A pilot, randomised, double blind, placebo-controlled, parallel groups, clinical trial to investigate the efficacy and safety of Cardiotrophin-1 (CT-1) in kidney transplantation. | |||||||||||||
Medical condition: Kidney transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000226-38 | Sponsor Protocol Number: 156-13-210 | Start Date*: 2015-01-08 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects ... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) SE (Completed) HU (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed) CZ (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003427-37 | Sponsor Protocol Number: SIRENA | Start Date*: 2007-02-05 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety | |||||||||||||
Medical condition: Autosomal-Dominant Polycystic Kidney Disease ADPKD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000985-12 | Sponsor Protocol Number: 1719-B | Start Date*: 2018-11-26 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Near-infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study | ||
Medical condition: Patients undergoing a living-donor kidney transplantation (living kidney donor and kidney recipient) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002092-14 | Sponsor Protocol Number: 0485-CL-E201 | Start Date*: 2008-01-21 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation – a multicenter, randomized, double-blind, placebo controlled, ... | |||||||||||||
Medical condition: kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) BE (Completed) CZ (Completed) IT (Completed) HU (Completed) DE (Completed) GB (Completed) AT (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000868-30 | Sponsor Protocol Number: NL76215.042.20 | Start Date*: 2021-02-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:RECOVAC consortium | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023017-65 | Sponsor Protocol Number: B1871019 | Start Date*: 2011-03-17 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) SK (Completed) LT (Completed) IT (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002807-21 | Sponsor Protocol Number: VitaD-1 | Start Date*: 2008-10-15 | ||||||||||||||||
Sponsor Name:MUW, Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse | ||||||||||||||||||
Full Title: VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome | ||||||||||||||||||
Medical condition: Vitamin D deficiency in kidney transplant recipients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003167-58 | Sponsor Protocol Number: WO29074 | Start Date*: 2014-04-14 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CAR... | |||||||||||||
Medical condition: ADVANCED RENAL CELL CARCINOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) FR (Completed) RO (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000995-13 | Sponsor Protocol Number: DECODE-CKD | Start Date*: 2022-01-26 | |||||||||||
Sponsor Name:Department of Cardiology, Herlev and Gentofte hospital | |||||||||||||
Full Title: A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
